* The Competition and Markets Authority (CMA) uses independent groups of panel members for phase 2 markets and mergers decisions.
* Each independent group contains a minimum of three panel members.
* Each group is led by an inquiry chair.
* Martin Coleman is the Panel Chair and an Inquiry Chair.
* Kirstin Baker, Margot Daly, and Cyrus Mehta are Inquiry Chairs.
* Martin Coleman, Kirstin Baker, Margot Daly, and Cyrus Mehta have had their biographies and disclosures of interest updated.
* Richard Feasey was removed as an Inquiry Chair.
* Humphrey Battcock, Mark Thatcher, and David Thomas were removed as panel members.
* Ulrike Hotopp, John Thanassoulis, Claire Whyley, Sheila McClelland, and Jeremy Newman were removed as panel members due to the end of their terms.
* Juliet Lazarus was added as a new panel member.
* Nine additional new members were added to the CMA panel.

The Competition and Markets Authority (CMA) utilizes independent groups of panel members to make decisions regarding phase 2 markets and mergers work. Each group consists of at least three members and is directed by an inquiry chair. Current inquiry chairs include Martin Coleman, who also serves as Panel Chair, Kirstin Baker, Margot Daly, and Cyrus Mehta.
The composition of this panel is subject to frequent updates, including the appointment of new members, the removal of individuals at the end of their terms, and the updating of biographies and disclosures of interest. These disclosures are maintained to ensure transparency regarding the interests of those overseeing regulatory decisions.

This is a technical transparency log, a administrative record designed to signal institutional integrity. The strongest version of this narrative is that the CMA operates with a rigorous, rotating system of independent oversight where conflicts of interest are proactively disclosed and terms of service are strictly observed to prevent regulatory capture.
The source type is a government disclosure page, triggering SKEPTICAL MODE. However, this text contains no persuasive arguments, emotive appeals, or strategic framing; it is a chronological list of administrative changes. It provides the "what" of transparency without providing the "how" or "why" regarding the specific criteria used for appointments or the nature of the disclosed interests.
The driving paradigm is one of bureaucratic accountability. It assumes that the mere act of listing changes and updating disclosures is sufficient to establish independence. The second-order consequence is that while the process is transparent, the actual influence of these "disclosures of interest" on decision-making remains opaque to the public.
Patterns detected: none
If this were part of an influence campaign, a bad actor would use these lists to "name and shame" specific members by linking their disclosed interests to specific regulatory outcomes to create a narrative of corruption. The actual content is a neutral record and does not match an attack pattern.
Bridge Questions:
1. What specific criteria determine when a "disclosure of interest" requires an update?
2. How does the CMA reconcile a member's disclosed interest with their assignment to a specific inquiry?
3. What is the process for selecting the "independent" members added to the panel?